Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study.

Morgan RM, Steele RJ, Nabi G, McCowan C.

J Urol. 2013 Oct;190(4):1207-12. doi: 10.1016/j.juro.2013.04.044. Epub 2013 Apr 19.

PMID:
23608675
2.

Rising incidence of prostate cancer in Scotland: increased risk or increased detection?

Brewster DH, Fraser LA, Harris V, Black RJ.

BJU Int. 2000 Mar;85(4):463-72; discussion 472-3.

3.

The impact of socio-economic circumstances on overall and grade-specific prostate cancer incidence: a population-based study.

Shafique K, Oliphant R, Morrison DS.

Br J Cancer. 2012 Jul 24;107(3):575-82. doi: 10.1038/bjc.2012.289. Epub 2012 Jul 3.

4.

Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.

Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P.

J Natl Cancer Inst. 2010 Sep 8;102(17):1336-43. doi: 10.1093/jnci/djq265. Epub 2010 Aug 19.

PMID:
20724726
5.
6.

Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996.

Threlfall TJ, English DR, Rouse IL.

Med J Aust. 1998 Jul 6;169(1):21-4.

PMID:
9695697
7.
8.
9.

Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.

Loeb S, Nadler RB, Roehl KA, Antenor JA, Catalona WJ.

J Urol. 2007 May;177(5):1745-8.

PMID:
17437803
10.

Prevalence of prostate specific antigen testing for prostate cancer in elderly men.

Dyche DJ, Ness J, West M, Allareddy V, Konety BR.

J Urol. 2006 Jun;175(6):2078-82.

PMID:
16697807
11.

Prostate-specific antigen levels in men aged 70 years and over: findings from the CHAMP study.

Litchfield MJ, Cumming RG, Smith DP, Naganathan V, Le Couteur DG, Waite LM, Blyth FM, Handelsman DJ.

Med J Aust. 2012 Apr 2;196(6):395-8.

PMID:
22471541
12.

Changing relationship between socioeconomic status and prostate cancer incidence.

Liu L, Cozen W, Bernstein L, Ross RK, Deapen D.

J Natl Cancer Inst. 2001 May 2;93(9):705-9.

PMID:
11333293
13.

Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.

Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE.

Eur Urol. 2012 May;61(5):865-74. doi: 10.1016/j.eururo.2011.11.007. Epub 2011 Nov 12.

PMID:
22104593
14.

Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality.

Tseng YD, Chen MH, Beard CJ, Martin NE, Orio PF, Loffredo M, Renshaw AA, Choueiri TK, Hu JC, Kantoff PW, D'Amico AV, Nguyen PL.

J Urol. 2012 Jun;187(6):2068-73. doi: 10.1016/j.juro.2012.01.073. Epub 2012 Apr 11.

PMID:
22498212
15.

[Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].

Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E.

Arch Esp Urol. 2005 Jun;58(5):403-11. Spanish.

PMID:
16078781
16.

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.

Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS.

Cancer Causes Control. 1998 Oct;9(5):519-27.

PMID:
9934717
17.

Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.

Konety BR, Bird VY, Deorah S, Dahmoush L.

J Urol. 2005 Nov;174(5):1785-8; discussion 1788.

PMID:
16217287
18.

Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.

Meigs JB, Barry MJ, Oesterling JE, Jacobsen SJ.

J Gen Intern Med. 1996 Sep;11(9):505-12.

PMID:
8905498
19.

Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.

Roberts RO, Bergstralh EJ, Peterson NR, Bostwick DG, Lieber MM, Jacobsen SJ.

J Urol. 2000 May;163(5):1471-5.

PMID:
10751860
20.

Prostate-specific antigen testing of older men.

Carter HB, Landis PK, Metter EJ, Fleisher LA, Pearson JD.

J Natl Cancer Inst. 1999 Oct 20;91(20):1733-7.

Supplemental Content

Support Center